📰 3 sources covering this story

US FDA advisers back Replimune skin cancer drug trial data

First covered 16 hrs ago · latest take 2 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

US FDA advisers back Replimune skin cancer drug trial data
Reuters
Reuters2 hrs ago
US FDA advisers back Replimune skin cancer drug trial data
US FDA advisers back Replimune skin cancer drug trial data  reuters.com
The Local Spain
The Local Spain14 hrs ago
What you need to know about skin cancer treatment in Spain
Skin cancer numbers in Spain have increased by 40 percent in the last four years. Here's what to know about it and the difference in treatments between public and private healthcare.
STAT News
STAT News🏁 first to report16 hrs ago
STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →